H.C. Wainwright downgraded Panbela Therapeutics to Neutral from Buy and removed the firm’s price target after the company announced Q1 results and offered a corporate update. Panbela is considering implementing a reverse stock split in the near future as it intends to pursue a listing on the U.S. Equity Listings Tier II of the Chicago Board Options Exchange, or CBOE. If successful, Panbela plans to conduct an offering to raise additional capital, notes the firm, which notes that these moves would result in further dilution.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBLA:
- Panbela Provides Business Update and Reports Q1 2024 Financial Results
- PBLA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Panbela Therapeutics announces issuance of new patent in US, Canada
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
- Panbela Therapeutics Updates ASPIRE Trial Timeline
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue